Enveric Biosciences (ENVB) Enterprise Value (QoQ) (2010 - 2026)
Enveric Biosciences (ENVB) Enterprise Value (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - |
| 10 | Enveric Biosciences | 5.62 Mn | -2.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.94% |
| Dec 31, 2025 | -24.48% |
| Sep 30, 2025 | -31.85% |
| Jun 30, 2025 | 33.64% |
| Mar 31, 2025 | -91.63% |
| Dec 31, 2024 | 27.98% |
| Sep 30, 2024 | 11.16% |
| Jun 30, 2024 | 44.89% |
| Mar 31, 2024 | -177.80% |
| Dec 31, 2023 | 46.37% |
| Sep 30, 2023 | 29.24% |
| Jun 30, 2023 | 47.81% |
| Mar 31, 2023 | 31.39% |
| Dec 31, 2022 | 17.62% |
| Sep 30, 2022 | -17.66% |
| Jun 30, 2022 | 19.93% |
| Mar 31, 2022 | -25.00% |
| Dec 31, 2021 | 19.08% |
| Sep 30, 2021 | -4.03% |
| Jun 30, 2021 | 9.00% |